APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chronic Kidney Disease Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Chronic Kidney Disease Drugs Market Outlook and Growth Opportunities 2026

26 December 2025195 pages

Choose your research edition.

Industry ResearchChronic Kidney Disease Drugs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Chronic Kidney Disease Drugs Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Chronic Kidney Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chronic Kidney Disease Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Chronic Kidney Disease Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Chronic Kidney Disease Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Chronic Kidney Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chronic Kidney Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chronic Kidney Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Chronic Kidney Disease Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Chronic Kidney Disease Drugs market include AstraZeneca, F. Hoffmann-La Roche Ltd, Keryx Biopharmaceuticals, Inc, Kissei Pharmaceutical Co., Ltd, AbbVie, Amgen, GlaxoSmithKline, Pfizer and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Chronic Kidney Disease Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chronic Kidney Disease Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chronic Kidney Disease Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chronic Kidney Disease Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Chronic Kidney Disease Drugs Segment by Company

AstraZeneca

F. Hoffmann-La Roche Ltd

Keryx Biopharmaceuticals, Inc

Kissei Pharmaceutical Co., Ltd

AbbVie

Amgen

GlaxoSmithKline

Pfizer

Sanofi

Teva Pharmaceutical Industries

Chronic Kidney Disease Drugs Segment by Type

Beta Blockers

Calcium Channel Blockers

Others

ACE Inhibitors

Chronic Kidney Disease Drugs Segment by Application

Hospitals

Specialty Clinics

Chronic Kidney Disease Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Chronic Kidney Disease Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Chronic Kidney Disease Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Chronic Kidney Disease Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Chronic Kidney Disease Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Kidney Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chronic Kidney Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Kidney Disease Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Chronic Kidney Disease Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Chronic Kidney Disease Drugs industry.

Chapter 3: Detailed analysis of Chronic Kidney Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Chronic Kidney Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Chronic Kidney Disease Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Chronic Kidney Disease Drugs Industry Trends Table 2. Chronic Kidney Disease Drugs Industry Drivers Table 3. Chronic Kidney Disease Drugs Industry Opportunities and Challenges Table 4. Chronic Kidney Disease Drugs Industry Restraints Table 5. Global Chronic Kidney Disease Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Chronic Kidney Disease Drugs Revenue Share by Company (2021-2026) Table 7. Global Chronic Kidney Disease Drugs Sales Volume by Company (W Tons) & (2021-2026) Table 8. Global Chronic Kidney Disease Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Chronic Kidney Disease Drugs Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Chronic Kidney Disease Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Chronic Kidney Disease Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Chronic Kidney Disease Drugs Company, Product Type & Application Table 13. Global Chronic Kidney Disease Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Chronic Kidney Disease Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Beta Blockers Table 18. Significant Companies of Calcium Channel Blockers Table 19. Significant Companies of Others Table 20. Significant Companies of ACE Inhibitors Table 21. Global Chronic Kidney Disease Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (W Tons) Table 22. Global Chronic Kidney Disease Drugs Sales Volume by Type (2021-2026) & (W Tons) Table 23. Global Chronic Kidney Disease Drugs Sales Volume by Type (2027-2032) & (W Tons) Table 24. Global Chronic Kidney Disease Drugs Sales Volume Share by Type (2021-2026) Table 25. Global Chronic Kidney Disease Drugs Sales Volume Share by Type (2027-2032) Table 26. Global Chronic Kidney Disease Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Chronic Kidney Disease Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Chronic Kidney Disease Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Chronic Kidney Disease Drugs Sales Value Share by Type (2021-2026) Table 30. Global Chronic Kidney Disease Drugs Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospitals Table 32. Significant Companies of Specialty Clinics Table 33. Global Chronic Kidney Disease Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (W Tons) Table 34. Global Chronic Kidney Disease Drugs Sales Volume by Application (2021-2026) & (W Tons) Table 35. Global Chronic Kidney Disease Drugs Sales Volume by Application (2027-2032) & (W Tons) Table 36. Global Chronic Kidney Disease Drugs Sales Volume Share by Application (2021-2026) Table 37. Global Chronic Kidney Disease Drugs Sales Volume Share by Application (2027-2032) Table 38. Global Chronic Kidney Disease Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Chronic Kidney Disease Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Chronic Kidney Disease Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Chronic Kidney Disease Drugs Sales Value Share by Application (2021-2026) Table 42. Global Chronic Kidney Disease Drugs Sales Value Share by Application (2027-2032) Table 43. Global Chronic Kidney Disease Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Tons) Table 44. Global Chronic Kidney Disease Drugs Sales by Region (2021-2026) & (W Tons) Table 45. Global Chronic Kidney Disease Drugs Sales Market Share by Region (2021-2026) Table 46. Global Chronic Kidney Disease Drugs Sales by Region (2027-2032) & (W Tons) Table 47. Global Chronic Kidney Disease Drugs Sales Market Share by Region (2027-2032) Table 48. Global Chronic Kidney Disease Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Chronic Kidney Disease Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Chronic Kidney Disease Drugs Sales Value Share by Region (2021-2026) Table 51. Global Chronic Kidney Disease Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Chronic Kidney Disease Drugs Sales Value Share by Region (2027-2032) Table 53. Global Chronic Kidney Disease Drugs Market Average Price (US$/Ton) by Region (2021-2026) Table 54. Global Chronic Kidney Disease Drugs Market Average Price (US$/Ton) by Region (2027-2032) Table 55. Global Chronic Kidney Disease Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Tons) Table 56. Global Chronic Kidney Disease Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Chronic Kidney Disease Drugs Sales by Country (2021-2026) & (W Tons) Table 58. Global Chronic Kidney Disease Drugs Sales Market Share by Country (2021-2026) Table 59. Global Chronic Kidney Disease Drugs Sales by Country (2027-2032) & (W Tons) Table 60. Global Chronic Kidney Disease Drugs Sales Market Share by Country (2027-2032) Table 61. Global Chronic Kidney Disease Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Chronic Kidney Disease Drugs Sales Value Market Share by Country (2021-2026) Table 63. Global Chronic Kidney Disease Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Chronic Kidney Disease Drugs Sales Value Market Share by Country (2027-2032) Table 65. AstraZeneca Company Information Table 66. AstraZeneca Business Overview Table 67. AstraZeneca Chronic Kidney Disease Drugs Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 68. AstraZeneca Chronic Kidney Disease Drugs Product Portfolio Table 69. AstraZeneca Recent Development Table 70. F. Hoffmann-La Roche Ltd Company Information Table 71. F. Hoffmann-La Roche Ltd Business Overview Table 72. F. Hoffmann-La Roche Ltd Chronic Kidney Disease Drugs Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 73. F. Hoffmann-La Roche Ltd Chronic Kidney Disease Drugs Product Portfolio Table 74. F. Hoffmann-La Roche Ltd Recent Development Table 75. Keryx Biopharmaceuticals, Inc Company Information Table 76. Keryx Biopharmaceuticals, Inc Business Overview Table 77. Keryx Biopharmaceuticals, Inc Chronic Kidney Disease Drugs Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 78. Keryx Biopharmaceuticals, Inc Chronic Kidney Disease Drugs Product Portfolio Table 79. Keryx Biopharmaceuticals, Inc Recent Development Table 80. Kissei Pharmaceutical Co., Ltd Company Information Table 81. Kissei Pharmaceutical Co., Ltd Business Overview Table 82. Kissei Pharmaceutical Co., Ltd Chronic Kidney Disease Drugs Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 83. Kissei Pharmaceutical Co., Ltd Chronic Kidney Disease Drugs Product Portfolio Table 84. Kissei Pharmaceutical Co., Ltd Recent Development Table 85. AbbVie Company Information Table 86. AbbVie Business Overview Table 87. AbbVie Chronic Kidney Disease Drugs Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 88. AbbVie Chronic Kidney Disease Drugs Product Portfolio Table 89. AbbVie Recent Development Table 90. Amgen Company Information Table 91. Amgen Business Overview Table 92. Amgen Chronic Kidney Disease Drugs Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 93. Amgen Chronic Kidney Disease Drugs Product Portfolio Table 94. Amgen Recent Development Table 95. GlaxoSmithKline Company Information Table 96. GlaxoSmithKline Business Overview Table 97. GlaxoSmithKline Chronic Kidney Disease Drugs Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 98. GlaxoSmithKline Chronic Kidney Disease Drugs Product Portfolio Table 99. GlaxoSmithKline Recent Development Table 100. Pfizer Company Information Table 101. Pfizer Business Overview Table 102. Pfizer Chronic Kidney Disease Drugs Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 103. Pfizer Chronic Kidney Disease Drugs Product Portfolio Table 104. Pfizer Recent Development Table 105. Sanofi Company Information Table 106. Sanofi Business Overview Table 107. Sanofi Chronic Kidney Disease Drugs Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 108. Sanofi Chronic Kidney Disease Drugs Product Portfolio Table 109. Sanofi Recent Development Table 110. Teva Pharmaceutical Industries Company Information Table 111. Teva Pharmaceutical Industries Business Overview Table 112. Teva Pharmaceutical Industries Chronic Kidney Disease Drugs Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 113. Teva Pharmaceutical Industries Chronic Kidney Disease Drugs Product Portfolio Table 114. Teva Pharmaceutical Industries Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. Chronic Kidney Disease Drugs Distributors List Table 118. Chronic Kidney Disease Drugs Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Chronic Kidney Disease Drugs Product Image Figure 2. Global Chronic Kidney Disease Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chronic Kidney Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Chronic Kidney Disease Drugs Sales (2021-2032) & (W Tons) Figure 5. Global Chronic Kidney Disease Drugs Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Chronic Kidney Disease Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Beta Blockers Image Figure 10. Calcium Channel Blockers Image Figure 11. Others Image Figure 12. ACE Inhibitors Image Figure 13. Global Chronic Kidney Disease Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (W Tons) Figure 14. Global Chronic Kidney Disease Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Chronic Kidney Disease Drugs Sales Volume Share by Type (2021-2032) Figure 16. Global Chronic Kidney Disease Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Chronic Kidney Disease Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Chronic Kidney Disease Drugs Sales Value Share by Type (2021-2032) Figure 19. Hospitals Image Figure 20. Specialty Clinics Image Figure 21. Global Chronic Kidney Disease Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (W Tons) Figure 22. Global Chronic Kidney Disease Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Chronic Kidney Disease Drugs Sales Volume Share by Application (2021-2032) Figure 24. Global Chronic Kidney Disease Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Chronic Kidney Disease Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Chronic Kidney Disease Drugs Sales Value Share by Application (2021-2032) Figure 27. Global Chronic Kidney Disease Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Tons) Figure 28. Global Chronic Kidney Disease Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Chronic Kidney Disease Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Chronic Kidney Disease Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Chronic Kidney Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. North America Chronic Kidney Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Chronic Kidney Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Chronic Kidney Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Chronic Kidney Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Chronic Kidney Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Chronic Kidney Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. South America Chronic Kidney Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Chronic Kidney Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Chronic Kidney Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Chronic Kidney Disease Drugs Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Chronic Kidney Disease Drugs Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Beta Blockers
  • Calcium Channel Blockers
  • Others
  • ACE Inhibitors
Applications
  • Hospitals
  • Specialty Clinics
Companies covered
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Keryx Biopharmaceuticals, Inc
  • Kissei Pharmaceutical Co., Ltd
  • AbbVie
  • Amgen
  • GlaxoSmithKline
  • Pfizer
  • Sanofi
  • Teva Pharmaceutical Industries

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Chronic Kidney Disease Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Chronic Kidney Disease Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Chronic Kidney Disease Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Chronic Kidney Disease Drugs Market Dynamics
  1. 2.1 Chronic Kidney Disease Drugs Industry Trends
  2. 2.2 Chronic Kidney Disease Drugs Industry Drivers
  3. 2.3 Chronic Kidney Disease Drugs Industry Opportunities and Challenges
  4. 2.4 Chronic Kidney Disease Drugs Industry Restraints
3 Chronic Kidney Disease Drugs Market by Company
  1. 3.1 Global Chronic Kidney Disease Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Chronic Kidney Disease Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Chronic Kidney Disease Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Chronic Kidney Disease Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Chronic Kidney Disease Drugs Company Ranking (2024-2026)
  6. 3.6 Global Chronic Kidney Disease Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Chronic Kidney Disease Drugs Company Product Type and Application
  8. 3.8 Global Chronic Kidney Disease Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Chronic Kidney Disease Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Chronic Kidney Disease Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Chronic Kidney Disease Drugs Market by Type
  1. 4.1 Chronic Kidney Disease Drugs Type Introduction
  2. 4.1.1 Beta Blockers
  3. 4.1.2 Calcium Channel Blockers
  4. 4.1.3 Others
  5. 4.1.4 ACE Inhibitors
  6. 4.2 Global Chronic Kidney Disease Drugs Sales Volume by Type
  7. 4.2.1 Global Chronic Kidney Disease Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Chronic Kidney Disease Drugs Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Chronic Kidney Disease Drugs Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Chronic Kidney Disease Drugs Sales Value by Type
  11. 4.3.1 Global Chronic Kidney Disease Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Chronic Kidney Disease Drugs Sales Value by Type (2021-2032)
  13. 4.3.3 Global Chronic Kidney Disease Drugs Sales Value Share by Type (2021-2032)
5 Chronic Kidney Disease Drugs Market by Application
  1. 5.1 Chronic Kidney Disease Drugs Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Specialty Clinics
  4. 5.2 Global Chronic Kidney Disease Drugs Sales Volume by Application
  5. 5.2.1 Global Chronic Kidney Disease Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Chronic Kidney Disease Drugs Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Chronic Kidney Disease Drugs Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Chronic Kidney Disease Drugs Sales Value by Application
  9. 5.3.1 Global Chronic Kidney Disease Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Chronic Kidney Disease Drugs Sales Value by Application (2021-2032)
  11. 5.3.3 Global Chronic Kidney Disease Drugs Sales Value Share by Application (2021-2032)
6 Chronic Kidney Disease Drugs Regional Sales and Value Analysis
  1. 6.1 Global Chronic Kidney Disease Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chronic Kidney Disease Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Chronic Kidney Disease Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Chronic Kidney Disease Drugs Sales by Region (2027-2032)
  5. 6.3 Global Chronic Kidney Disease Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Chronic Kidney Disease Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Chronic Kidney Disease Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Chronic Kidney Disease Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Chronic Kidney Disease Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Chronic Kidney Disease Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Chronic Kidney Disease Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Chronic Kidney Disease Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Chronic Kidney Disease Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Chronic Kidney Disease Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Chronic Kidney Disease Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Chronic Kidney Disease Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Chronic Kidney Disease Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Chronic Kidney Disease Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Chronic Kidney Disease Drugs Sales Value Share by Country, 2025 VS 2032
7 Chronic Kidney Disease Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Chronic Kidney Disease Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Chronic Kidney Disease Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Chronic Kidney Disease Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Chronic Kidney Disease Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Chronic Kidney Disease Drugs Sales by Country (2027-2032)
  6. 7.4 Global Chronic Kidney Disease Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Chronic Kidney Disease Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Chronic Kidney Disease Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Chronic Kidney Disease Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Chronic Kidney Disease Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Chronic Kidney Disease Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AstraZeneca
  2. 8.1.1 AstraZeneca Company Information
  3. 8.1.2 AstraZeneca Business Overview
  4. 8.1.3 AstraZeneca Chronic Kidney Disease Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AstraZeneca Chronic Kidney Disease Drugs Product Portfolio
  6. 8.1.5 AstraZeneca Recent Developments
  7. 8.2 F. Hoffmann-La Roche Ltd
  8. 8.2.1 F. Hoffmann-La Roche Ltd Company Information
  9. 8.2.2 F. Hoffmann-La Roche Ltd Business Overview
  10. 8.2.3 F. Hoffmann-La Roche Ltd Chronic Kidney Disease Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 F. Hoffmann-La Roche Ltd Chronic Kidney Disease Drugs Product Portfolio
  12. 8.2.5 F. Hoffmann-La Roche Ltd Recent Developments
  13. 8.3 Keryx Biopharmaceuticals, Inc
  14. 8.3.1 Keryx Biopharmaceuticals, Inc Company Information
  15. 8.3.2 Keryx Biopharmaceuticals, Inc Business Overview
  16. 8.3.3 Keryx Biopharmaceuticals, Inc Chronic Kidney Disease Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Keryx Biopharmaceuticals, Inc Chronic Kidney Disease Drugs Product Portfolio
  18. 8.3.5 Keryx Biopharmaceuticals, Inc Recent Developments
  19. 8.4 Kissei Pharmaceutical Co., Ltd
  20. 8.4.1 Kissei Pharmaceutical Co., Ltd Company Information
  21. 8.4.2 Kissei Pharmaceutical Co., Ltd Business Overview
  22. 8.4.3 Kissei Pharmaceutical Co., Ltd Chronic Kidney Disease Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Kissei Pharmaceutical Co., Ltd Chronic Kidney Disease Drugs Product Portfolio
  24. 8.4.5 Kissei Pharmaceutical Co., Ltd Recent Developments
  25. 8.5 AbbVie
  26. 8.5.1 AbbVie Company Information
  27. 8.5.2 AbbVie Business Overview
  28. 8.5.3 AbbVie Chronic Kidney Disease Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AbbVie Chronic Kidney Disease Drugs Product Portfolio
  30. 8.5.5 AbbVie Recent Developments
  31. 8.6 Amgen
  32. 8.6.1 Amgen Company Information
  33. 8.6.2 Amgen Business Overview
  34. 8.6.3 Amgen Chronic Kidney Disease Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Amgen Chronic Kidney Disease Drugs Product Portfolio
  36. 8.6.5 Amgen Recent Developments
  37. 8.7 GlaxoSmithKline
  38. 8.7.1 GlaxoSmithKline Company Information
  39. 8.7.2 GlaxoSmithKline Business Overview
  40. 8.7.3 GlaxoSmithKline Chronic Kidney Disease Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline Chronic Kidney Disease Drugs Product Portfolio
  42. 8.7.5 GlaxoSmithKline Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Chronic Kidney Disease Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Chronic Kidney Disease Drugs Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Sanofi
  50. 8.9.1 Sanofi Company Information
  51. 8.9.2 Sanofi Business Overview
  52. 8.9.3 Sanofi Chronic Kidney Disease Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Sanofi Chronic Kidney Disease Drugs Product Portfolio
  54. 8.9.5 Sanofi Recent Developments
  55. 8.10 Teva Pharmaceutical Industries
  56. 8.10.1 Teva Pharmaceutical Industries Company Information
  57. 8.10.2 Teva Pharmaceutical Industries Business Overview
  58. 8.10.3 Teva Pharmaceutical Industries Chronic Kidney Disease Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Teva Pharmaceutical Industries Chronic Kidney Disease Drugs Product Portfolio
  60. 8.10.5 Teva Pharmaceutical Industries Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Chronic Kidney Disease Drugs Value Chain Analysis
  2. 9.1.1 Chronic Kidney Disease Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Chronic Kidney Disease Drugs Sales Mode & Process
  6. 9.2 Chronic Kidney Disease Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Chronic Kidney Disease Drugs Distributors
  9. 9.2.3 Chronic Kidney Disease Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst